Department of Orthopedics and Sports Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Bone Joint J. 2021 Jun;103-B(6 Supple A):13-17. doi: 10.1302/0301-620X.103B6.BJJ-2020-2401.R1.
Infection complicating primary total knee arthroplasty (TKA) is a common reason for revision surgery, hospital readmission, patient morbidity, and mortality. Increasing incidence of methicillin-resistant (MRSA) is a particular concern. The use of vancomycin as prophylactic agent alone or in combination with cephalosporin has not demonstrated lower periprosthetic joint infection (PJI) rates, partly due to timing and dosing of intravenous (IV) vancomycin administration, which have proven important factors in effectiveness. This is a retrospective review of a consecutive series of primary TKAs examining incidence of PJI, adverse reactions, and complications using IV versus intraosseous (IO) vancomycin at 30-day, 90-day, and one-year follow-up.
A retrospective review of 1,060 patients who underwent TKA between May 2016 to July 2020 was performed. There were 572 patients in the IV group and 488 in the IO group, with minimal 30 days of follow-up. Patients were followed up at regularly scheduled intervals (two, six, and 12 weeks). No differences between groups for age, sex, BMI, or baseline comorbidities existed. The IV group received an IV dose of 15 mg/kg vancomycin given over an hour preceding skin incision. The IO group received a 500 mg dose of vancomycin mixed in 150 ml of normal saline, injected into proximal tibia after tourniquet inflation, before skin incision. All patients received an additional dose of first generation cephalosporin. Evaluation included preoperative and postoperative serum creatinine values, tourniquet time, and adverse reactions attributable to vancomycin.
Incidence of PJI with minimum 90-day follow-up was 1.4% (eight knees) in the IV group and 0.22% (one knee) in IO group (p = 0.047). This preliminary report demonstrated an reduction in the incidence of infection in TKA using IO vancomycin combined with a first-generation cephalosporin. While the study suffers from limitations of a retrospective, multi-surgeon investigation, early findings are encouraging.
IO delivery of vancomycin after tourniquet inflation is a safe and effective alternative to IV administration, eliminating the logistical challenges of timely dosing. Cite this article: 2021;103-B(6 Supple A):13-17.
初次全膝关节置换术(TKA)后感染是翻修手术、再次住院、患者发病率和死亡率的常见原因。耐甲氧西林金黄色葡萄球菌(MRSA)的发病率不断上升尤其令人担忧。万古霉素单独或与头孢菌素联合作为预防剂并不能降低假体周围关节感染(PJI)的发生率,部分原因是静脉(IV)万古霉素给药的时间和剂量,这已被证明是有效性的重要因素。这是一项回顾性连续系列初次 TKA 的研究,检查了使用静脉(IV)与骨内(IO)万古霉素在 30 天、90 天和 1 年随访时的 PJI 发生率、不良反应和并发症。
对 2016 年 5 月至 2020 年 7 月期间接受 TKA 的 1060 例患者进行了回顾性分析。IV 组有 572 例,IO 组有 488 例,随访时间至少为 30 天。患者定期(2、6 和 12 周)随访。两组在年龄、性别、BMI 或基线合并症方面无差异。IV 组在皮肤切开前 1 小时内给予 15mg/kg 的 IV 万古霉素。IO 组在止血带充气后,在皮肤切开前,将 500mg 万古霉素混入 150ml 生理盐水,注入胫骨近端。所有患者均接受第一代头孢菌素的额外剂量。评估包括术前和术后血清肌酐值、止血带时间和万古霉素相关的不良反应。
在接受至少 90 天随访的患者中,IV 组的 PJI 发生率为 1.4%(8 例),IO 组为 0.22%(1 例)(p=0.047)。这项初步报告表明,使用 IO 万古霉素联合第一代头孢菌素可降低 TKA 的感染发生率。虽然该研究存在多外科医生回顾性研究的局限性,但早期发现令人鼓舞。
止血带充气后静脉内输注万古霉素是一种安全有效的替代方法,可消除及时给药的后勤挑战。